In 2021, Rücker et al. performed an exploratory post hoc analysis of the CALGB 10603/RATIFY trial aiming to assess the molecular landscape of FLT3-ITD-mutated AML and to determine the prognostic impact of ITD IS in a total of 555 AML patients carrying FLT3-ITD [84]. Here, FLT3 is linked to acute myeloid leukemia.